Business Wire

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart ...

Scribe’s CRISPR epigenetic silencing technology, ELXR, demonstrated dramatic and sustained lowering of LDL-C by up to 67% for nearly 6 months in non-human primates – without altering DNA sequence. In ...
Business Wire

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...
Nasdaq

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the ...
GEN

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies ...
GEN

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR ...